Provided by Tiger Trade Technology Pte. Ltd.

Keros Therapeutics, Inc.

11.08
-0.0900-0.81%
Post-market: 11.080.00000.00%16:10 EDT
Volume:143.83K
Turnover:1.60M
Market Cap:219.69M
PE:-3.57
High:11.34
Open:11.25
Low:11.03
Close:11.17
52wk High:22.55
52wk Low:9.69
Shares:19.83M
Float Shares:18.25M
Volume Ratio:1.19
T/O Rate:0.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1046
EPS(LYR):2.30
ROE:-17.16%
ROA:-11.78%
PB:0.84
PE(LYR):4.82

Loading ...

Keros Therapeutics - Initiates Phase 2 Trial of Rinvatercept in Duchenne Muscular Dystrophy

THOMSON REUTERS
·
Aug 04

Keros Therapeutics Q2 Net Income USD -28.71 Million

THOMSON REUTERS
·
Aug 04

Keros Therapeutics - Cash and Cash Equivalents $257.60 Mln as of June 30, 2026

THOMSON REUTERS
·
Aug 04

Keros Therapeutics - Expects Cash to Fund Operations into First Half of 2028

THOMSON REUTERS
·
Aug 04

Keros Therapeutics to Receive $20 Million Takeda Milestone Payment for Elritercept Phase 3 Dosing

Reuters
·
Jul 31

Keros Therapeutics - Received $200 Mln Upfront from Takeda, Eligible for over $1.10 Bln in Milestones

THOMSON REUTERS
·
Jul 31

Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda

THOMSON REUTERS
·
Jul 31

Keros Therapeutics - Appoints Annita Tanini Interim Principal Financial Officer Effective August 4, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 23

Keros Therapeutics Names Annita Tanini Interim CFO as Keith Regnante Resigns

Reuters
·
Jul 23

Keros Therapeutics Director Jean Jacques Bienaime Buys USD 10,610 in Common Shares

Reuters
·
Jul 18

Keros Therapeutics Director Anne Prener Files Initial Beneficial Ownership Statement

Reuters
·
Jul 07

Keros Therapeutics’ TROPOS Trial Termination: What It Means for KROS Investors

TIPRANKS
·
Jul 03

Keros Therapeutics Appoints Anne Prener to Its Board of Directors

THOMSON REUTERS
·
Jun 26

Keros Therapeutics director Jean Jacques Bienaime buys $10,190 of common shares

Reuters
·
Jun 18

Keros director Charles W. Newton sells 550 shares for $5,522

Reuters
·
Jun 16

Keros Therapeutics director Nima Farzan sells 2,625 shares for $28,163.25

Reuters
·
Jun 09

Keros Therapeutics director Julius Knowles sells 2,625 shares for $28,163.25

Reuters
·
Jun 09

Keros Therapeutics director Seth Alpna disposes of 2,625 shares worth $28,140.00

Reuters
·
Jun 06

Keros Therapeutics holds annual shareholder meeting

Reuters
·
Jun 04

Keros Therapeutics CEO to join Goldman Sachs Global Healthcare Conference fireside chat

Reuters
·
Jun 02